YAP1 Amplification as a Prognostic Factor of Definitive Chemoradiotherapy in Nonsurgical Esophageal Squamous Cell Carcinoma

Cancer Medicine - United Kingdom
doi 10.1002/cam4.2761
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Neoadjuvant vs Definitive Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Patients

World Journal of Surgical Oncology
SurgeryOncology
2018English

Lymph Node Enlargement After Definitive Chemoradiotherapy for Clinical Stage I Esophageal Squamous Cell Carcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2014English

Value and Application of Trimodality Therapy or Definitive Concurrent Chemoradiotherapy in Thoracic Esophageal Squamous Cell Carcinoma

Cancer
Cancer ResearchOncology
2017English

The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma After Concurrent Chemoradiotherapy

Cancer Research and Treatment
Cancer ResearchOncology
2016English

SOX2 Antagonizes WWC1 to Drive YAP1 Activation in Esophageal Squamous Cell Carcinoma

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

Prognostic Significance of FAM3C in Esophageal Squamous Cell Carcinoma

Diagnostic Pathology
Forensic MedicineMedicinePathologyHistology
2015English

A Molecular Prognostic Model Predicts Esophageal Squamous Cell Carcinoma Prognosis

PLoS ONE
Multidisciplinary
2014English

BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated With Cisplatin- Or Docetaxel-Based Chemotherapy/Chemoradiotherapy

PLoS ONE
Multidisciplinary
2013English

The Prognostic Value of B7-H6 in Esophageal Squamous Cell Carcinoma

Scientific Reports
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy